5-MAPDI

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields =

| verifiedrevid =

| IUPAC_name = 1-(2,3-Dihydro-1H-inden-5-yl)-N-methylpropan-2-amine

| image = 5-MAPDI Structure.svg

| tradename =

| pregnancy_category =

| legal_CA =

| legal_DE =

| legal_UK =

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 1310153-27-5

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 7NDJ44KFB8

| ATC_prefix = none

| ATC_suffix =

| PubChem = 57461970

| ChemSpiderID = 26679339

| C=13 | H=19 | N=1

| smiles = CNC(Cc1ccc2c(c1)CCC2)C

| StdInChI = 1S/C13H19N/c1-10(14-2)8-11-6-7-12-4-3-5-13(12)9-11/h6-7,9-10,14H,3-5,8H2,1-2H3

| StdInChIKey = MHBKJTHGGWQKSG-UHFFFAOYSA-N

}}

5-MAPDI (also known as Indanylmethylaminopropane or IMP) is an entactogenic amphetamine derivative which is structurally related to MDMA as well as to dihydrobenzofuran derivatives such as 5-MAPDB and 6-MAPDB, and has been sold as a designer drug. It has reportedly been sold over grey-market websites since around 2014, although the first definitive identification was not made until September 2016 by a forensic laboratory in Slovenia.[http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf European Monitoring Center for Drugs and Drug Addiction – Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA]